ReconAfrica closed a C$21.85 million bought-deal offering on Sept. 10, selling 29,932,200 units at C$0.73 with the over-allotment option fully exercised, and will use the net proceeds for a horizontal sidetrack and production testing program at Kavango West 1X in the Huttenberg formation.
A fully exercised over-allotment option turned ReconAfrica's upsized financing into C$21.85 million of committed capital, and the Calgary explorer now has the money to drill laterally into the Huttenberg formation at its Kavango West 1X well in northeastern Namibia. The company sold 29,932,200 units at C$0.73 apiece in the bought-deal offering that closed Sept. 10, each unit bundling one common share with half a share-purchase warrant exercisable at C$0.93 through Sept. 10, 2029.
"The market has now funded the test rather than the story," said Omar Tariq, an energy analyst who covers frontier exploration for Edgen. "The over-allotment being fully exercised is the tell — underwriters do not take that allocation unless the book is covered, and it means the company can run the Huttenberg test without returning to equity markets mid-program."
The offering was led by Research Capital Corporation as lead underwriter and sole bookrunner, alongside Canaccord Genuity Corp. and ATB Cormark Capital Markets. ReconAfrica paid C$1,282,910.76 in cash commission and issued 1,757,412 broker warrants at C$0.73, plus a C$15,000 advisory fee and 6,000 advisory warrants on identical terms. The warrants are expected to begin trading on the TSX Venture Exchange under the symbol RECO.WT.D in the following week, subject to final exchange acceptance. The financing was completed by prospectus supplement to a short form base shelf prospectus dated April 13, 2026, filed with securities regulators in every Canadian province except Québec.
The capital is earmarked for the primary reservoir in the Huttenberg formation and, alternatively, the secondary reservoir in the Elandshoek formation. That distinction matters for how the program is judged. A horizontal sidetrack re-enters an existing wellbore and drills laterally through the target interval, which gives a far larger contact area with the reservoir than the vertical hole and produces a more meaningful flow test. For a company whose licences span roughly 13 million contiguous acres across the Damara Fold Belt and Kavango Rift Basin in Namibia, Angola and Botswana, a single well result is the only near-term evidence that can move the equity.
The dilution arithmetic is the counterweight. The 29,932,200 units represent a meaningful expansion of the share count at C$0.73, and the 1,757,412 broker warrants plus 6,000 advisory warrants add further potential supply at the same strike. The C$0.93 warrant exercise price sits roughly 27 percent above the offering price, so those warrants only convert if the stock re-rates — which ties the company's future funding capacity directly to the well outcome. ReconAfrica also operates the Ngulu block offshore central Gabon, covering 1,214 square kilometers and containing the Loba oil field discovery, giving it a second asset base if the Kalahari program disappoints.
The last comparable moment for the equity was the transition from seismic and stratigraphic work to a funded flow test, when the shares traded on the promise of a basin rather than on production data. Frontier exploration names typically trade on a binary: the pre-result period carries the full option value, and the result either confirms a commercial accumulation or resets the valuation toward the value of the remaining acreage. ReconAfrica's own risk disclosure, in its annual information form dated April 14, 2026 for the period ended Dec. 31, 2025, flags that actual results may differ materially from the forward-looking statements attached to the use of proceeds.
What happens next is a drilling and testing sequence rather than a scheduled disclosure. The company has not yet disclosed a spud date, a target depth for the lateral, or an expected timeline for flow rates from the Huttenberg test. Until those numbers arrive, the shares carry the financing overhang and the warrant strike as their two hard reference points, and the C$0.73 offering price becomes the level the market will measure the raise against. If the sidetrack flows at commercial rates, the C$0.93 warrants move into the money and the company gains a self-funding path; if the test is inconclusive, the next financing is priced against a lower share count of proven value.
This article is for informational purposes only and does not constitute investment advice.
